Adagene (NASDAQ:ADAG) vs. Lifecore Biomedical (NASDAQ:LFCR) Head to Head Survey

Adagene (NASDAQ:ADAG) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Adagene and Lifecore Biomedical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67 million	23.04	-$17.61 million	N/A	N/A
Lifecore Biomedical	$128.87 million	1.37	-$35.26 million	($0.94)	-5.01

Adagene has higher earnings, but lower revenue than Lifecore Biomedical.

Risk & Volatility

Adagene has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Adagene and Lifecore Biomedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1	0	2	2	3.00
Lifecore Biomedical	2	1	1	0	1.75

Adagene presently has a consensus target price of $8.00, suggesting a potential upside of 114.53%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 38.15%. Given Adagene’s stronger consensus rating and higher possible upside, equities analysts clearly believe Adagene is more favorable than Lifecore Biomedical.

Profitability

This table compares Adagene and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Lifecore Biomedical	-25.43%	N/A	-14.40%

Insider and Institutional Ownership

9.5% of Adagene shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Adagene beats Lifecore Biomedical on 8 of the 12 factors compared between the two stocks.

About Adagene

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.